Pfizer CEO Albert Bourla stated that uncertainty over Trump’s planned pharmaceutical tariffs is deterring new U.S. investments in research and manufacturing, according to CNBC. In the company's first-quarter earnings call,

Unlike other companies grappling with evolving trade policy, Pfizer didn't revise its full-year outlook Tuesday.

For years, Pfizer was the only drugmaker with treatments for the disease, called ATTR-CM, but BridgeBio’s CEO said in an interview that there’s room for other products as more doctors become aware of the disease and patients get diagnosed earlier. Read more.